Series of reports on the “Second China Hospital Pharmacy Forum” (2)-Congratulations on the establishment of the Preparatory Committee of the Comparative Effectiveness (CER) Professional Committee of the China Council for the Promotion of Pharmaceuticals

Source: Song Ruilin, executive chairman of China drug promotion association on August 5, 2011, presided over the Establishment Ceremony of "Preparatory Committee of CER Professional Committee of China drug promotion association" and CER training meeting held in Dalian More than 200 doctors, pharmacists and academician Zhang Boli of the Chinese Academy of engineering, as well as leaders from the national development and Reform Commission, the Ministry of industry and information technology, the Ministry of human resources and social security, the State Food and Drug Administration and other departments gathered to discuss how to ensure the medical safety and efficiency of patients and reasonable costs through comparative effectiveness (CER) research Song Ruilin, executive chairman of China pharmaceutical promotion association, said that we should fully understand the necessity and urgency of carrying out and using cer research; in order to open the era of CER research and application in China, today we set up the "Preparatory Committee of China pharmaceutical promotion association's cer professional committee", the main purpose of which is to promote the formal establishment of the professional committee of comparative effectiveness and start cer research in hospitals Comparative effectiveness research (CER) is an empirical summary of the comparison of different treatment schemes and clinical advantages and disadvantages At the same time, the concept of benefit cost is introduced It is characterized by reflecting the "real world" clinical practice and evaluating the benefit cost Wang Yongjun, vice president of Beijing Tiantan Hospital, which is about to launch China's first cer research platform, is talking about China's implementation of cer It is necessary to say that many clinical practices lack of effective evidence, such as the treatment of a large number of cardiovascular diseases, the basis for the selection of various statins; from the perspective of coordinating with China's medical reform and controlling medical costs, patients and the government also need a truly effective and affordable medical treatment Wang Yongjun, vice president of Beijing Tiantan Hospital, studied the case analysis and the report of design and methodology to provide medical and health benefits for the whole people, which is a long cherished wish of all countries, but controlling medical expenses has become a common problem of all countries, including China "In 2009, the United States invested $1.1 billion to launch the national cer research The starting point is that the government needs an affordable health care," Wang Yongjun said in a keynote speech entitled challenges and opportunities in comparative effectiveness research Li Guoqing, director of the drug evaluation center of the State Food and drug administration, made a report on the role of post marketing clinical evaluation in the research and development of new drugs Li Guoqing, director of the drug evaluation center of the State Food and drug administration, made a report on the role of post marketing clinical evaluation in the development of new drugs Huo Yong, Professor of Cardiology in the first hospital of Peking University, Li Hao, deputy director of the quality control center for brain stroke treatment of the Ministry of health and other experts reported on the case analysis, design and methodology of the CER study Li Hao, deputy director of the quality control center of brain apoplexy of the Ministry of health, made a report on the case analysis and design and methodology of CER research by Wang Yilong, director of Beijing Tiantan Hospital Methodology professionals were also trained at the conference Representatives of the meeting had a heated discussion and answer questions on relevant professional issues It is reported that at present, CERs of China Council for the promotion of drugs The members of the Preparatory Committee of the professional committee mainly include: Wang Yongjun, vice president of Beijing Tiantan Hospital; huoyong, Professor of Cardiology, the first hospital of Peking University; Li Hao, deputy director of brain stroke TCM quality control center of the Ministry of health; Ding liming, chairman of Zhejiang Beida Pharmaceutical Co., Ltd.; Xu Xiping, chairman and chief section of Beijing AoSA Pharmaceutical Research Center Co., Ltd Chen Wei, Ph.D., Duke University, USA The members of the Preparatory Committee include experts from the pharmaceutical industry, medical clinical and scientific research institutions, giving full play to the important purpose of China pharmaceutical promotion association to promote the alliance of industry, University and research, and the number of members is still increasing The establishment and development of the theory, method and technical system of comparative effectiveness research (CER) is to meet the above-mentioned challenges of medical reform in various countries CER It is a kind of clinical research which is driven by controlling medical cost, standardizing medical behavior and taking patients as the center to evaluate different prevention, diagnosis, treatment, rehabilitation and other technologies, drugs and equipment in the real world, to provide diagnosis and treatment information for patients and doctors, to provide health policy basis for policy makers, and finally in the individual and the whole population Improve the level of medical services Comparative effectiveness research is closely related to evidence-based medicine and health technology evaluation, and it is almost impossible to carry out independently It also needs the participation of economists, clinical experts, statisticians and other professional talents (Information Department of China Pharmaceutical Association)